Although we evaluated urinary MCP‐1 concentration as a candidate biomarker of the severity of diabetic nephropathy,12 monitoring of pharmacological inhibition of CCR2 may be required to further investigate the efficacy of PG in future definitive trials. This evidence concerns the gene CCR2 and diabetic kidney disease.